252.16

0.10% 0.25

Axsome Therapeutics Inc (AXSM)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AXSM? Forum Prognose

Schlusskurs vom Vortag:

$251.91

Offen:

$251.13

24-Stunden-Volumen:

519.42K

Relative Volume:

0.72

Marktkapitalisierung:

$12.98B

Einnahmen:

$708.24M

Nettoeinkommen (Verlust:

$-188.30M

KGV:

-67.44

EPS:

-3.7392

Netto-Cashflow:

$-70.99M

1W Leistung:

+2.36%

1M Leistung:

+10.73%

6M Leistung:

+70.38%

1J Leistung:

+148.19%

1-Tages-Spanne:

$248.64

$254.84

1-Wochen-Bereich:

$247.69

$257.93

52-Wochen-Spanne:

$96.09

$257.93

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Firmenname

Axsome Therapeutics Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

(212) 332-3241

Adresse

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Mitarbeiter

925

Twitter

Nächster Verdiensttermin

2026-08-03

Neueste SEC-Einreichungen

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AXSM Axsome Therapeutics Inc	252.16	13.04B	708.24M	-188.30M	-70.99M	-3.7392
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-02-24	Eingeleitet	Wolfe Research	Outperform
2026-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-10-01	Eingeleitet	B. Riley Securities	Buy
2025-09-03	Fortgesetzt	Wells Fargo	Overweight
2025-07-03	Fortgesetzt	Morgan Stanley	Overweight
2025-06-03	Eingeleitet	Oppenheimer	Outperform
2025-04-07	Eingeleitet	Jefferies	Buy
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-31	Bestätigt	Mizuho	Outperform
2024-09-03	Eingeleitet	Wells Fargo	Overweight
2024-08-06	Hochstufung	BofA Securities	Neutral → Buy
2024-07-22	Eingeleitet	Needham	Buy
2024-04-29	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-06	Eingeleitet	UBS	Buy
2024-01-25	Eingeleitet	RBC Capital Mkts	Outperform
2023-12-13	Eingeleitet	Citigroup	Buy
2023-08-08	Hochstufung	BofA Securities	Underperform → Neutral
2023-01-05	Eingeleitet	Piper Sandler	Neutral
2022-11-01	Eingeleitet	Loop Capital	Buy
2022-09-07	Fortgesetzt	Mizuho	Buy
2021-08-10	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-06-10	Eingeleitet	Berenberg	Buy
2021-01-08	Eingeleitet	Jefferies	Buy
2020-12-16	Eingeleitet	Mizuho	Buy
2020-09-29	Eingeleitet	BofA Securities	Underperform
2020-09-10	Eingeleitet	Morgan Stanley	Overweight
2020-04-28	Bestätigt	H.C. Wainwright	Buy
2020-04-14	Eingeleitet	Cowen	Outperform
2019-12-30	Bestätigt	H.C. Wainwright	Buy
2019-12-17	Bestätigt	H.C. Wainwright	Buy
2019-12-16	Bestätigt	Guggenheim	Buy
2019-10-16	Eingeleitet	Guggenheim	Buy
2019-09-18	Eingeleitet	William Blair	Outperform
2019-05-28	Eingeleitet	SunTrust	Buy
2019-05-23	Bestätigt	H.C. Wainwright	Buy
2019-04-08	Eingeleitet	SVB Leerink	Outperform
2019-03-15	Bestätigt	H.C. Wainwright	Buy
2016-10-03	Fortgesetzt	Brean Capital	Buy
2015-12-15	Eingeleitet	Cantor Fitzgerald	Buy
2015-12-14	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

Jun 16, 2026

3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool

Jun 16, 2026

Jun 15, 2026

Axsome presents data on narcolepsy treatments at sleep conference By Investing.com - Investing.com South Africa

Jun 15, 2026

Axsome presents data on narcolepsy treatments at sleep conference - Investing.com

Jun 15, 2026

Axsome Therapeutics Presents New Data on AXS-12 and Solriamfetol at SLEEP 2026 Conference - Quiver Quantitative

Jun 15, 2026

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 - GlobeNewswire

Jun 15, 2026

Axsome Therapeutics (AXSM) Stock Analysis: 57% Revenue Growth Propels Exciting Prospects - DirectorsTalk Interviews

Jun 15, 2026

Landscape Capital Management L.L.C. Sells 3,983 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 15, 2026

Jun 14, 2026

First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Nicholas Investment Partners LP Purchases 42,907 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Eventide Asset Management LLC Sells 175,172 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Jun 13, 2026

The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily

Jun 13, 2026

Rhenman & Partners Asset Management AB Reduces Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 13, 2026

Jun 12, 2026

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits

Jun 12, 2026

Jun 11, 2026

Axsome therapeutics director Roger Jeffs sells $141,655 in shares By Investing.com - Investing.com India

Jun 11, 2026

Axsome therapeutics director Roger Jeffs sells $141,655 in shares - Investing.com UK

Jun 11, 2026